tecentriq
roche registration gmbh - atezolizumabas - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antinavikiniai vaistai - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kaip monotherapy fluorouracilu ir folino suaugusių pacientų su lokaliai išplitusio arba metastazavusio nsclc po ankstesnės chemoterapijos metu. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kaip monotherapy fluorouracilu ir folino suaugusių pacientų su lokaliai išplitusio arba metastazavusio nsclc po ankstesnės chemoterapijos metu. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
hemlibra
roche registration limited - emicizumab - hemofilija a - antihemoraginiai - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra gali būti naudojami visose amžiaus grupėse.
aciclovir siromed
stada arzneimittel ag - acikloviras - kremas - 50 mg/g - aciclovir
acyclovir stada
stada arzneimittel ag - acikloviras - kremas - 50 mg/g - aciclovir
aminoplasmal b.braun 10%
b.braun melsungen ag - izoleucinas/leucinas/lizino acetatas/metioninas/fenilalaninas/lizinas, monohidratas/treoninas/triptofanas/valinas/argininas/histidinas/alaninas/glicinas/asparto rūgštis/glutamo rūgštis/prolinas/serinas/tirozinas - infuzinis tirpalas - 5 g/8,9 g/5,74 g/4,4 g/4,7 g/3,12 g/4,2 g/1,6 g/6,2 g/11,5 g/3 g/10,5 g/12 g/5,6 g/7,2 g/5,5 g/2,3 g/0,4 g/1000 ml - amino acids
aminoplasmal hepa 10%
b.braun melsungen ag - izoleucinas/leucinas/lizino acetatas/metioninas/fenilalaninas/treoninas/triptofanas/valinas/argininas/histidinas/glicinas/alaninas/prolinas/asparto rūgštis/asparaginas monohidratas/acetilcisteinas/glutamo rūgštis/ornitino hidrochloridas/serinas/acetiltirozinas - infuzinis tirpalas - 8,8 g/13,6 g/10,6 g/1,2 g/1,6 g/4,6 g/1,5 g/10,6 g/8,8 g/4,7 g/6,3 g/8,3 g/7,1 g/2,5 g/0,55 g/0,8 g/5,7 g/1,66 g/3,7 g/0,86 g/1000 ml; 8,8 g/13,6 g/10,6 g/1,2 g/1,6 g/4,6 g/1,5 g/10,6 g/8,8 g/4,7 g/6,3 g/8,3 g/7,1 g/2,5 g/0,55 g/0,8 g/5,7 g/1,66 g/3,7 g/0,86 g/10 - amino acids
bromhexin berlin-chemie
berlin-chemie ag (menarini group) - bromheksinas - dengtos tabletės - 8 mg - bromhexine
delufen
richard bittner ag - sinapis nigra d2/euphorbium d6/pulsatilla pratensis d6/luffa operculata d12/hydrargyrum biiodatum d12 - nosies purškalas (tirpalas) - 0,01 ml/0,1 ml/0,1 ml/0,1 ml/0,1 ml/ml
dormicum
roche lietuva, uab - midazolamas - injekcinis ar infuzinis tirpalas - 5 mg/ml; 7,5 mg - midazolam
ultrapen la 300 mg/ml, injekcinė suspensija
norbrook laboratories (ireland) limited. (airija) - injekcinė suspensija - 1 ml yra: benzilpenicilino prokaino - 300 mg. - galvijams ir kiaulėms, sergančioms infekcinėmis ligomis, kurių sukėlėjai jautrūs penicilinui, gydyti.